Gary Cai

Q: What is Gary Cai email address?

Email Gary Cai at cgary8@gmail.com and gcai@inmunebio.com. This email is the most updated Gary Cai's email found in 2026.

Q: How to contact Gary Cai?

To contact Gary Cai send an email to cgary8@gmail.com or gcai@inmunebio.com. (updated on April 02, 2024)

VP Regulatory Affairs at INmune Bio Inc. | Greater Chicago Area

About Gary Cai

Gary Cai serves as the Vice President of Regulatory Affairs at INmune Bio Inc., where he plays a pivotal role in shaping the company’s regulatory landscape. With over 20 years of extensive experience in the pharmaceutical industry, Gary leads a dedicated team focused on planning and executing regulatory strategies that align with both domestic and international healthcare legislation. His deep understanding of regulatory requirements across the US, EU, Canada, and other global markets enables him to navigate complex regulatory environments effectively.

At INmune Bio, Gary has been instrumental in developing and implementing innovative global regulatory strategies that facilitate successful submissions to regulatory bodies such as the FDA, EMA, Health Canada, and MHRA. His expertise in Chemistry, Manufacturing, and Controls (CMC), Clinical Regulatory Affairs, and Good Manufacturing Practices (GMP) ensures that the company’s products meet stringent regulatory standards throughout their lifecycle. Gary’s strong analytical skills allow him to dissect intricate projects and propose realistic solutions, ensuring that the company remains compliant while advancing its research and development initiatives.

In addition to his strategic oversight, Gary actively represents INmune Bio in high-stakes meetings with health authorities, where he negotiates development plans and addresses inquiries. His proficiency in regulatory submissions and clinical trials, combined with his adeptness in utilizing databases and Microsoft Office tools, positions him as a key asset in driving the company’s mission to deliver groundbreaking therapies. Gary’s leadership not only enhances INmune Bio’s regulatory framework but also contributes significantly to the advancement of innovative treatments in the biopharmaceutical sector.

Gary Cai Work